

IMSUT Hospital

Center for Clinical Safety and Infection Control

医療安全・感染制御センター

The Center for Clinical Safety and Infection Control consists of the Department of Medical Safety Management and the Department of Infection Prevention and Control and supports for providing safe medical care.

Department of Medical Safety Management

医療安全管理部

Head, Professor	Narikazu Boku, M.D., D.M.Sc.	教授 博士(医学)	朴 成 和
Associate Professor	Susumu Aikou, M.D., D.M.Sc.	准教授 博士(医学)	愛 甲 丞
Associate Professor	Motohisa Yamamoto, M.D., D.M.Sc.	准教授 博士(医学)	山 本 元 久
Nurse Manager	Nozomi Linzbichler	看護師長	リンツビヒラ希
Director of Pharmacy	Seiichiro Kuroda	薬剤部長	黒 田 誠一郎
Associate Professor	Ayako Kamisato, Ph.D.	准教授 博士(法学)	神 里 彩 子

Department Medical Safety Management is responsible for carrying out medical safety in order to prevent incidents and accidents beforehand and deliver safe medical care to patients. At our hospital, we mainly have focused on hematological malignancies, infectious diseases, immune diseases, but in recent years, robotic surgery and chemotherapy are also increasing. We try to respond appropriately to such medical activities.

Department of Infection Prevention and Control

感染制御部

Head, Senior Assistant Professor	Eisuke Adachi, M.D., D.M.Sc.	講師 博士(医学)	安 達 英 輔
Professor	Hiroshi Yotsuyanagi, M.D., D.M.Sc.	教授 博士(医学)	四 柳 宏
Assistant Professor	Ikeuchi Kazuhiko, M.D., D.M.Sc.	助教 博士(医学)	池 内 和 彦
Nurse Manager	Miya Kogayu	看護師長	小 粥 美 香
Nurse Manager	Fumie Kameda	看護師長	亀 田 史 絵
Pharmacist	Mika Yamamura	薬剤師	山 村 美 桂
Clinical laboratory technician	Hiroko Shibata	臨床検査技師	柴 田 浩 子

Department of Infection Prevention and Control builds ICT (Infection Control Team) and AST (Antimicrobial Stewardship Team) to promote the practice of hospital infection control and prevent the spread of antimicrobial resistant organisms. The ICT consists of infection control doctors, an infection control nurse, a pharmacist, a clinical laboratory technicians and an administrative staff.

Nosocomial infection control against prolonged COVID-19 and persistent viral shedding

We reported two cases of COVID-19 with prolonged viral shedding. Each of the two cases was a patient with HIV/AIDS and a patient with malignant lymphoma who was using an anti-CD20 antibody product. Both cases required long-term infection control measures against COVID-19 in private rooms in the hospital.

1. Nagai H, Saito M, Adachi E, Sakai-Tagawa Y, Yamayoshi S, Kiso M, Kawamata T, Koga M, Kawano Y, Tsutsumi T, Yotsuyanagi H. Casirivimab/Imdevimab for Active COVID-19 Pneumonia Which Persisted for Nine Months in a Patient with Follicular Lymphoma during Anti-CD20 Therapy. *Jpn J Infect Dis.* 2022 Nov 22;75(6):608-611
2. Adachi E, Saito M, Koga M, Tsutsumi T, Yotsuyanagi H. Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS. *Intern Med.* 2022 Nov 15;61(22):3459-3462.
3. Tokunaga M, Yoshikawa T, Boku N, Nishida Y, Tanahashi T, Yamada T, Haruta S, Etoh T, Hirahara N, Kawachi Y, Tsuji K, Kinoshita T, Kanazawa T, Tokumoto N, Fujita J, Terashima M. Impact of COVID-19 on gastric cancer treatment in Japanese high-volume centers: a JCOG stomach cancer study group survey. *Surg Today.* 52(2): 231-238, 2022. doi: 10.1007/s00595-021-02329-y.